🔥 TRENDING Andhra Pradesh set to become a new hub... Dr Anil Kumar Takes Charge as TSRTC Vi... Berhampur University scientists discov... Odisha Orders Early Evacuation in Sout... Cyclone Akvan Triggers District‑wise R... सतनवाड़ा, शिवपुरी में वन विभाग ने 140...
16 Nov 2026•
ગુજરાતી मराठी ਪੰਜਾਬੀ বাংলা
Glenmark Pharma Debuts Axitinib Tablets, Boosting Portfolio
📷 Image: Wikimedia Commons / Pdreijnders
Business

Glenmark Pharma Debuts Axitinib Tablets, Boosting Portfolio

✍️ Udaipur Kiran 🗓 16 Nov 2026, 01:47 PM 👁 18
Share: 💬 WhatsApp 📘 Facebook 𝕏 Post

Glenmark Pharmaceuticals has announced the launch of its new Axitinib tablets, a targeted cancer therapy, marking a significant expansion in its oncology portfolio. The move is expected to strengthen the company's market position in the competitive oncology segment.

Glenmark Pharmaceuticals announced the launch of Axitinib tablets, a targeted therapy for certain cancers, today.
The drug, a tyrosine kinase inhibitor approved for renal cell carcinoma, will now be available in India under the brand name "Axitinib".
This addition expands Glenmark’s oncology portfolio and is expected to increase its revenue in the growing cancer treatment market.
The company plans to invest in research and development as well as marketing to support the new product.
Glenmark anticipates that Axitinib will capture a significant share of the competitive oncology segment in India.
📲Get App